Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas by Shulkin, Barry L. et al.
Current Trends in Functional Imaging of
Pheochromocytomas and
Paragangliomas
BARRY L. SHULKIN,a IOANNIS ILIAS,b JAMES C. SISSON,c
AND KAREL PACAKd
aDivision of Nuclear Medicine, Department of Radiological Sciences, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105-2794, USA
bDepartment of Pharmacology, Medical School, University of Patras,
Rion-GR-26504, Greece
cDivision of Nuclear Medicine, Department of Radiology, University of
Michigan Medical Center, 1500 East Medical Center Drive, UH B1G 505D,
Ann Arbor, Michigan 48109-0028, USA
dReproductive Biology and Medicine Branch, National Institute of Child Health
and Human Development, National Institutes of Health, Bethesda, Maryland
20892-1109, USA
ABSTRACT: Most pheochromocytomas/paragangliomas should be eval-
uated with anatomical imaging (computed tomography or magnetic
resonance imaging) followed by functional imaging (nuclear medicine
modalities). Functional imaging assures that the tumor is indeed a
pheochromocytoma/paraganglioma and enables more thorough local-
ization, especially detecting as many lesions as possible (in particular
for metastatic disease). Functional imaging for pheochromocytomas/
paragangliomas, can use radiolabled ligands specific for pathways of
synthesis, metabolism, and inactivation of catecholamines or nonspe-
cific ligands. In an overview of the available nuclear medicine modali-
ties, we summarize the accumulated experience and recommend when
functional imaging should be applied to patients with pheochromocy-
toma/paraganglioma.
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INTRODUCTION
Although pheochromocytomas are predominantly sporadic, about 24%
of patients with apparent sporadic pheochromocytoma may be carriers of
germline mutations that entail a predisposition for extra-adrenal and often mul-
tifocal disease.1 About 26–35% of these tumors are metastastic,2–5 and about
10% present with metastatic disease at initial diagnosis.6 In the context of the
clinical evaluation of pheochromocytoma/paraganglioma, anatomical imaging
with computed tomography (CT) or magnetic resonance (MR) should be done
in all patients. After anatomical imaging is performed, functional (nuclear
medicine) modalities are used to prove that the tumor is indeed pheochromo-
cytoma/paraganglioma, as well as to detect as many lesions as possible (for
metastatic disease) and to choose the appropriate therapeutic plan. Nuclear
medicine modalities can be categorized into those that are specific for the cat-
echolamine synthesis/secretion pathway and those that are nonspecific, that is,
they reflect other aspects of tumor pathophysiology.
Most pheochromocytoma/paraganglioma cells (chromaffin cells) are distin-
guished from other tumor cells in that they express the norepinephrine transport
system (hNET).7 The latter is responsible for the uptake of norepinephrine and
epinephrine from the synaptic cleft into the presynaptic neuron of the sym-
pathetic nervous system. hNET thus not only terminates neural transmission
by removal of the neurotransmitter norepinephrine but also enables specific
functional imaging. In this manuscript we will review the results of imaging of
pheochromocytoma obtained with various radiotracers. We begin by describing
several radiotracers that depend upon hNET for transport to pheochromocy-
toma cells followed by tracers whose uptake and retention are independent of
hNET (FIG. 1).
SPECIFIC FUNCTIONAL IMAGING
Attempts to image pheochromocytoma by specific radiotracer techniques
began with the development of meta-iodobenzylguanidine (m-IBG) by
Wieland and colleagues at the University of Michigan.8 Sisson and colleagues
reported successful localization of pheochromocytomas using m-IBG.9 Ini-
tially, m-IBG was labeled with iodine-131. m-IBG labeled with iodine-123 has
become more common because of the characteristics of I-123, which makes it
a better radiolabel than iodine-131 for diagnostic evaluation of pheochromo-
cytoma. Relative to I-131, I-123 has a shorter half-life (13.2 h vs. 8 days), a
principal emission photon energy much closer to the 140 kEv of Tc-99m,
around which gamma cameras are designed (159 kEv I-123 vs. 364 kEv
I-131), and lack of beta particulate emission, which adds to the radiation bur-
den and limits the activity that can be administered. Because of the higher
emitted photon flux, I-123 m-IBG images contain about tenfold the number of
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FIGURE 1. Targets for functional imaging of pheochromocytomas/paragangliomas.
On the right are shown steps and molecules involved in the synthesis of catecholamines;
these are targets for radioligands specific for such cells. On the left are nonspecific tar-
gets. Molecules with asterisks are radiolabeled to be used for functional imaging. TH:
tyrosine hydroxylase; hNET: human norepinephrine transporter (responsible for re-uptake
of catecholamines); m-IBG: meta-iodobenzylguanidine; VMATs: vesicular monoamine
transporters (they transport m-IBG into norepinephrine and epinephrine storage vesi-
cles); LAT-1: large neutral amino acid transporter; L-DOPA: L-dihydroxyphenylalanine; L-
AADC: aromatic-L-amino acid decarboxylase; DBH: dopamine beta-hydroxylase; PNMT:
phenylethanolamine-N-methyltransferase; ST: somatostatin; OCT: octreotide; Glu: glu-
cose; FDG: 18-F-fluorodeoxyglucose; FDG-6-P: FDG-6-phosphate; Stop: not further
metabolized.
acquired counts as do those obtained with I-131 m-IBG; they are of much
higher quality; and tomographic images (SPECT – single photon emission
computed tomography) can be obtained for further localization (FIG. 2).
m-IBG is useful in localizing pheochromocytomas in any part of the body.
It is especially valuable in localizing extra-adrenal sites of pheochromocy-
toma, and pheochromocytoma in areas of the body previously operated upon,
where anatomic imaging is compromised by distortion of anatomy and the
presence of metallic clips that degrade anatomic-based images. a-IBG (amino-
iodobenzylguanidine) was synthesized as a kit-based formula that would allow
local production of the radiolabeled compound.10 Although pheochromocy-
tomas were readily identified using this compound, lung accumulation of a-IBG
was higher than that of m-IBG.
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FIGURE 2. The upper left panel is a 11-C-hydroxyephedrine (HED) PET image at 40
min and the upper right panel is a I-123-m-IBG (meta-iodobenzylguanidine) SPECT image
at 24 h of a 72-year-old patient with a mid-abdominal pheochromocytoma (hepatic uptake
is indicated with small white arrows; the tumor is indicated with the large dark arrow). The
lower left panel is a 11-C-HED PET image at 40 min and the lower right panel is a I-123-
m-IBG SPECT image at 24 h of a 60-year-old patient with malignant pheochromocytoma
(multiple foci of uptake are indicated with small dark arrows).
Positron emission tomography (PET) tracers present some advantages com-
pared with single photon-emitting tracers. PET tracers utilize PET cameras,
which inherently produce tomographic images with higher spatial resolution
than conventional scintigraphic imaging. PET tracers utilize shorter-lived iso-
topes, enabling higher doses to be administered for a similar radiation exposure.
Because of the short half-life, tracers that reflect different aspects of tumor bi-
ology could be administered in a single session.
The first positron-emitting tracer of the sympathetic nervous system suit-
able for administration in humans was m-hydroxyephedrine (HED). HED was
designed to image the sympathetic innervation of the heart. Structurally, it re-
sembles norepinephrine but is not susceptible to intracellular degradation by the
enzyme monoamine oxidase. m-HED was shown to accumulate in myocardium
by transport by the human norepinephrine transporter (hNET). It was labeled
with the positron emitter, carbon-11. C-11 has a half-life of only 20 min, thus
C-11 HED requires onsite synthesis as its short half-life precludes widespread
distribution. Shulkin and colleagues showed that outstanding functional images
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of pheochromocytomas could be obtained using C-11 HED and a PET cam-
era (FIG. 2).11 Pheochromocytomas were localized in 9 of 10 patients with
pheochromocytoma. High-quality functional images were acquired within
minutes of injection, and tumor to nontumor ratios were more favorable than
those of I-123 m-IBG. Trampal and colleagues have also reported excellent
results with C-11 HED.12 Because of the need for onsite synthesis, few centers
have access to this compound and it is not yet widely utilized.
Closely related to the endogenous neurotransmitter norepinephrine is the
catecholamine epinephrine. Like HED, epinephrine is labeled with C-11,
requiring onsite synthesis. Unlike HED, epinephrine is a substrate for the
catecholamine catabolic enzymes COMT (catechol-O-methyltransferase) and
MAO (monoamine oxidase), and thus its retention in myocardium requires in-
tact catecholamine storage vesicles. The majority of pheochromocytomas can
be visualized using C-11 epinephrine.13 However, the rate of successful local-
ization is less than that of m-IBG, and it is not likely that C-11 epinephrine will
replace m-IBG for functional imaging of pheochromocytoma. As with C-11
HED, uptake occurs quite rapidly and is sustained through the imaging period.
Another PET ligand that targets steps of catecholamine synthesis is F-18-
fluorodopamine (F-18-DA) (FIG. 3). PET with F-18-DA was performed in
18 patients with metastatic pheochromocytoma and was compared to planar
I-131-m-IBG scintigraphy. F-18-DA was superior to I-131-m-IBG: it localized
pheochromocytomas in all patients and showed numerous foci that were not
imaged with I-131-m-IBG scintigraphy.14 In more recent studies, PET with
F-18-DA was superior to I-123-m-IBG scintigraphy in imaging adrenal and/or
benign pheochromocytomas and paragangliomas (Pacak et al., unpublished
data).15
Fluorodopa was developed to image the dopaminergic elements of the cen-
tral nervous system. More recently it has been shown to provide functional
images of pheochromocytoma. In 14 patients, 17 sites of pheochromocytoma
were identified both by MRI and PET F-18 fluorodopa imaging.16 In 4 patients,
m-IBG scintigraphy was falsely negative. F-18 fluorodopa is presumably con-
verted into fluorodopamine and then transported into pheochromocytomas by
hNET, although the large neutral amino acid transporter may also contribute.
NONSPECIFIC FUNCTIONAL IMAGING
FDG (18-fluorodeoxyglucose) is used for the detection and management
of many types of tumors in children and adults. FDG portrays the glucose
metabolic activity of tumors, and its uptake and retention are unrelated to
catecholamine uptake and storage. FDG is now widely available commercially.
The first report of FDG uptake in pheochromocytoma involved two patients
whose pheochromocytomas did not accumulate mIBG. Further studies showed
that most benign and most malignant pheochromocytomas could be localized
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FIGURE 3. PET scans with F-18-fluorodopamine of patients with adrenal pheochro-
mocytomas: left panel shows a left adrenal pheochromocytoma (dark arrow) and right panel
shows a right adrenal pheochromocytoma (dark arrow).
with FDG PET.17 FDG PET appears particularly valuable for the localization
of pheochromocytomas that do not accumulate m-IBG or other tracers of the
sympathetic nervous system.17–19
Somatostatin receptor scintigraphy is of limited value in the localization of
pheochromocytoma. Both pheochromocytomas and paragangliomas express
somatostatin receptors.20–22 The octapeptide octreotide is an analogue of so-
matostatin that is chelated with diethylenetriaminepentaacetate (DTPA) and
labeled with indium-111 for diagnostic imaging. We have not found it useful
in the evaluation of pheochromocytomas in the abdomen because of its normal
intense accumulation in the liver, spleen, and kidneys, and excretion into the
gastrointestinal tract. It might be useful for identifying malignant/metastatic
pheochromocytomas or paragangliomas;23–29 such malignant/metastatic tu-
mors can be candidates for radiolabeled somatostatin analogue therapy.
NEWER FUNCTIONAL IMAGING LIGANDS
Newer potential functional imaging modalities specific for pheochromocy-
tomas/paragangliomas include PET with F-18-fluorobenzylguanidine.30 New
somatostatin receptor ligands, which are yet to be evaluated clinically, for
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SPECT31 or PET32–37 have been developed (they are nevertheless nonspecific
for pheochromocytomas/paragangliomas).
RECOMMENDATIONS AND PERSPECTIVES
In conclusion, regarding clinical practice, functional imaging evalua-
tion should be done after anatomical imaging with CT or MRI. Further-
more, we propose that functional imaging be performed in all patients with
extra-adrenal, metastatic, or multiple pheochromocytomas, norepinephrine-
secreting pheochromocytomas, and epinephrine-secreting adrenal pheochro-
mocytomas larger than 5 cm in diameter. Additionally, functional imag-
ing modalities should be chosen in the postsurgical setting, when bio-
chemical evaluation for pheochromocytoma is inconclusive and in particular
when anatomical imaging is negative. Specific functional imaging modalities
(m-IBG scintigraphy or PET with 18-F-DA, 18-F-DOPA, or 11-C-HED) are
to be used first, and if these turn out to be negative, nonspecific modalities
(somatostatin receptor scintigraphy or FDG-PET) should follow.
In future, we anticipate that at centers with PET departments and access to
specific PET ligands, most functional imaging procedures for pheochromocy-
toma/paraganglioma may be PET studies.
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